New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
08:02 EDTLJPCLa Jolla Pharmaceutical announces final dosing in GCS-100 phase 2 trial
La Jolla Pharmaceutical announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease and has collected the final data for evaluation of the primary endpoint. The primary efficacy endpoint is the change in estimated glomerular filtration rate from baseline to the average at day 50 and 57 in each GCS-100 dose group compared to placebo. The primary endpoint will be reached if the difference in eGFR between either GCS-100 dose group and placebo has a significance of less than 10%. Of the 121 subjects with Stage 3b or 4 CKD enrolled, 117 subjects completed the study with no discontinuation due to an adverse event. Subjects were randomly assigned 1:1:1 to treatment with placebo, 1.5 or 30 mg/m2 of GCS-100. In addition, randomization was stratified by baseline renal function, defined by eGFR values of 15-29 and 30-44 mL/min/1.73m2. Once randomized, subjects received eight consecutive weekly doses of their assigned treatment with a follow-up four weeks after treatment.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:02 EDTLJPCLa Jolla 4.8M share Spot Secondary priced at $10.50
The deal range was $10.40-$10.60. Jefferies acted as sole book running manager for the offering.
July 22, 2014
16:01 EDTLJPCLa Jolla files to sell common stock, no amount given
La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes. Jefferies LLC is acting as sole book-runner for the offering.
July 15, 2014
09:21 EDTLJPCOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTLJPCLa Jolla Pharma announces pre-clinical data for LJPC-1010 in NASH
Subscribe for More Information
July 11, 2014
11:39 EDTLJPCLa Jolla price target raised to $45 from $34 at Wedbush
Subscribe for More Information
July 9, 2014
15:35 EDTLJPCLa Jolla price target raised to $38 on '501 potential in CRH at Noble Financial
05:34 EDTLJPCLa Jolla to host investor conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use